BIO-key Answers the Call for Secure, Modern Authentication with New Passwordless Innovations at the 2025 Gartner(R) IAM Summit: North America

(NASDAQ:BKYI), GRAPEVINE, Texas & HOLMDEL, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) — BIO-key(R) International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions enabling phoneless, tokenless, passwordless, and phishing-resistant authentication, today announced its participation in the 2025 Gartner(R) Identity & Access Management Summit: North America, December 8-10 in […]

Ascent Solar Technologies Announces Up To $5.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

(NASDAQ:ASTI), THORNTON, Colo., Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascent Solar Technologies, Inc. (NASDAQ: ASTI) (“Ascent” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,025,643 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up

ASUS Announces Always Incredible Virtual Launch Event for CES 2026

(TAI:2357.TW), KEY POINTS Next-Level AI PCs: ASUS to unveil a new generation of adaptive, AI-driven devices with powerful NPUs that deliver intelligent, seamless experiences Comprehensive Ecosystem: ASUS to spotlight three key AI scenarios, Workspace AI, Creator AI, and Everyday AI Inspiring Innovation: ASUS is deeply integrating AI into everyday life, delivering intelligent computing solutions that

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenstrom Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

(NasdaqGM:NRIX), Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenstrom macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-free survival (PFS) have not been reached Encouraging efficacy and favorable tolerability support continued development of bexobrutideg in Waldenstrom macroglobulinemia

Nukik Corporation and Agnico Eagle Sign MOU to Advance Commercial Negotiations & Technical Collaboration on the Kivalliq Hydro-Fibre Link

RANKIN INLET, Nunavut, Dec. 08, 2025 (GLOBE NEWSWIRE) — Nukik Corporation and Agnico Eagle Mines Limited (“Agnico Eagle“) are pleased to announce the signing of a Memorandum of Understanding (“MOU”) to formalize commercial negotiations and technical collaboration on the Kivalliq Hydro-Fibre Link (“KHFL”) — a transformative infrastructure project designed to bring clean, reliable energy and

Digits Launches Ask Digits, a 24/7 AI Assistant for Real-Time Financial Answers and Actions

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Digits, the world's first Agentic General Ledger(TM) (AGL(R)), officially launched Ask Digits, a new AI-powered assistant that gives business owners and accountants a unified place to ask questions, take action, and interact with their financials in real time. Ask Digits serves as the central interface to Digits'

Clip Money Inc. Announces Expanded Partnership with Centennial Delivering Cash Management Solutions to 1600+ Retailers

(TSX-V:CLIP),(OTC US:CLPMF),(Other OTC:CLPMF), ATLANTA, Dec. 08, 2025 (GLOBE NEWSWIRE) — Clip Money Inc. (TSX-V: CLIP) (OTCQB: CLPMF) (“Clip Money” or the “Company”), operator of North America's only multi-bank cash deposit system for businesses with over 8,000 deposit accepting locations, is pleased to announce an expanded portfolio partnership with Centennial, a leading retail and mixed-use real

CALIFORNIA BANCORP ANNOUNCES FIRST CASH DIVIDEND

(NASDAQ:BCAL), San Diego, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — California Bancorp (the “Company”) (Nasdaq: BCAL), the holding company for California Bank of Commerce, N.A. (the “Bank”), announces that its Board of Directors has approved the Company's first quarterly cash dividend. This strategic decision reflects the Company's strong financial performance and commitment to creating shareholder

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

(NASDAQ:SABS),(NASDAQ:SABSW), MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held

Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society

– NON-MTS & BILATERAL MTLE: First data reported from non-MTS and bilateral MTLE subjects demonstrate robust seizure reduction – LOW DOSE COHORT: 89% median reduction in disabling seizures for unilateral subjects with MTS at the primary efficacy evaluation period of 7-12 months post administration (n=9) – HIGH DOSE COHORT: 78% median reduction in disabling seizures

Scroll to Top